[Form 4] Humacyte, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Humacyte, Inc. (HUMA) reported an equity award to its Chief Medical Officer, Shamik J. Parikh, on a Form 4. On 11/16/2025, Parikh acquired 311,100 shares of Humacyte common stock at a stated price of $0, linked to a grant of restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of common stock. The first 50% of these RSUs will vest on May 15, 2026, with the remaining 50% vesting on May 15, 2027, subject to the award’s conditions. Following this reported transaction, Parikh beneficially owns 318,600 shares of Humacyte common stock, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parikh Shamik J

(Last) (First) (Middle)

2525 EAST NORTH CAROLINA HIGHWAY 54

(Street)

DURHAM NC 27713

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Humacyte, Inc. [ HUMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	11/16/2025		A		311,100	A	$0	318,600	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was granted restricted stock units (RSUs), which represent a contingent right to receive one share of Common Stock for each RSU. The first 50% of the RSUs will vest on May 15, 2026, after which the remaining 50% of the RSUs will vest on May 15, 2027.

Remarks:

	/s/ Shamik J. Parikh by Dale A. Sander as Attorney-in-Fact	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Humacyte (HUMA) disclose in this Form 4?

Humacyte disclosed that its Chief Medical Officer, Shamik J. Parikh, acquired 311,100 shares of common stock on 11/16/2025, tied to a restricted stock unit (RSU) grant.

How many Humacyte shares does the reporting person now own?

After the reported transaction, Shamik J. Parikh beneficially owns 318,600 shares of Humacyte, Inc. common stock, held directly.

What are the vesting terms of the Humacyte RSU grant reported for HUMA?

The RSU grant vests in two equal installments: 50% of the RSUs vest on May 15, 2026, and the remaining 50% vest on May 15, 2027, for each unit delivering one share of common stock.

Who is the insider reporting this Humacyte (HUMA) transaction?

The reporting person is Shamik J. Parikh, who serves as Chief Medical Officer of Humacyte, Inc.

What type of securities were involved in this Humacyte Form 4?

The transaction involves common stock of Humacyte, Inc., associated with a grant of restricted stock units (RSUs), each RSU representing a contingent right to receive one share.

At what price were the Humacyte shares acquired in this insider transaction?

The 311,100 shares of Humacyte common stock reported were acquired at a stated price of $0, reflecting their issuance in connection with the RSU grant rather than an open-market purchase.